努力缩小临床应用的基础编辑器
1Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan 31151, Republic of Korea.
International journal of molecular sciences
|March 13, 2025
概括
基因编辑器 (BEs) 提供精确的基因编辑,没有DNA双链断裂. 缩小这些基于CRISPR的工具对于有效提供基因疗法至关重要,克服了当前体内应用的局限性.
科学领域:
- 生物技术是生物技术.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 聚类定期间隔的短平行体重复 (CRISPR) 技术已经彻底改变了基因编辑.
- 基编辑器 (BEs) 提供精确的单核酸编辑,而不会诱导DNA双链断裂 (DSB).
- 由于BEs的大小,阻碍了有效的传递,特别是通过腺相关病毒 (AAV) 载体,限制了临床应用.
研究的目的:
- 为了强调减少基编辑器 (BE) 尺寸对于治疗基因编辑的重要性.
- 审查最近在削减银行企业规模的战略方面的进展.
- 讨论正在进行的努力,以解决其他BE限制,以改善体内基因编辑.
主要方法:
- 审查基于CRISPR的基因编辑工具的文献,特别是基因编辑器.
- 分析减少BE大小的策略,包括域截断和组件更换.
- 检查克服交付和与BE相关的其他挑战的方法.
主要成果:
- 已经开发出了BEs的各种规模缩小策略.
- 这些策略旨在保持编辑效率,同时提高交付能力.
- 在解决增强体内基因编辑的其他局限性方面正在取得进展.
结论:
- 缩小基础编辑器 (BE) 对于其成功的临床翻译和高效的AAV中介交付至关重要.
- 目前正在进行的研究重点是通过解决尺寸和交付挑战来优化BEs用于治疗应用.
- 这些进展有望提高体内基因编辑疗法的疗效和安全性.
相关概念视频
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:12Statistical Software for Data Analysis and Clinical Trials
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
01:28Methods of Medium Optimization
Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...